Hematopoietic Stem Cell Approaches to Cancer

Publication date: October 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 5
Author(s): Jennifer E. Adair, Sara P. Kubek, Hans-Peter Kiem

Teaser

Hematopoietic stem cells (HSCs) are unique in their ability to self-renew and generate all blood lineages for the entire life. HSC modification affects red blood cells, platelets, lymphocytes, and myeloid cells. Chemotherapy can result in myelosuppression, limiting effective chemotherapy administration. For diseases like glioblastoma, high expression of methlylguanine methyltransferase can inactivate alkylating agent chemotherapy. Here we discuss how HSCs can be modified to overcome this resistance, permitting sensitization of tumors to chemotherapy while simultaneously protecting the hematopoietic system. We also discuss how HSCs can be harnessed to produce powerful tumor killing T cells, potentially benefitting and complementing T-cell–based immunotherapies.


http://ift.tt/2wPNICG